TD Cowen analyst Tyler Van Buren has maintained their bullish stance on MAZE stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyler Van Buren has given his Buy rating due to a combination of factors that suggest significant potential for Maze Therapeutics, Inc. The company is on the brink of two major value-creating events. The first is the upcoming Phase I biomarker data for MZE782, which focuses on Phe and Glu biomarkers and could pave the way for Phase II trials in PKU and CKD. This data is expected by the end of the current quarter.
Moreover, Maze Therapeutics is set to release topline data from the Phase II HORIZON study for MZE829 in AKD in the first quarter of 2026. The promising results from MZE782, particularly its potency compared to similar treatments, and its potential to address unmet needs in CKD patients, further support the positive outlook. These developments, coupled with the strategic approach to clinical trials, underpin Van Buren’s optimistic assessment of the company’s stock.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $34.00 price target.